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The details bedevil DCOR
J Silver1
Calcium-free oral phosphorus binders were heralded as a 
striking new development for patients with chronic kidney 
disease, promising a reduction in morbidity and mortality from 
cardiovascular disease. Sevelamer hydrochloride was the first such 
drug introduced to the market. Dialysis Clinical Outcomes Revisited 
(DCOR) is an outcomes study on the effect of sevelamer compared 
with calcium-based phosphorus binders in dialysis patients. It does 
not show a clear superiority of one compound over the other.
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Patients with chronic kidney disease 
die of cardiovascular causes related to a 
number of factors. There is now abun-
dant evidence that phosphorus (P) 
retention in these patients is a major 
contributing factor. There have been 
elegant laboratory studies showing that 
a high extracellular P is transported 
into the cell by a sodium-phosphate 
cotransporter (Na-Pi) (type III) and that 
the resultant increase in intracellular P 
leads the vascular smooth muscle cells 
to adopt the genetic and cellular proper-
ties of bone cells.1 An increased serum 
calcium and parathyroid hormone act 
to stimulate the transport of P into the 
cells. The mechanism of vascular calci-
ﬁcation is in fact multifactorial, with a 
number of factors involved that either 
stimulate or inhibit the process.2 These 
proteins act either as inhibitors of vas-
cular calcification, such as fetuin A, 
osteopontin, matrix gla protein (MGP), 
bone morphogenetic protein 7 (BMP7), 
and pyrophosphate, or as stimulators, 
such as transforming growth factor-β, 
BMP2, parathyroid hormone-related 
protein (PTHrP), and so on. However, 
P retention is an extremely important 
factor in the formation of vascular 
hydroxyapatite—so much so, that the 
process of ossiﬁcation has aptly been 
termed ‘phossification’ to emphasize 
the important contribution of P. There 
is therefore every reason to control the 
serum P in patients with chronic kidney 
disease, especially those on dialysis.
The algorithm for the treatment of 
these patients is well established. Dietary 
P restriction is impossible considering 
the recommended protein requirements 
and is respected more in its breach than 
in its practice. Dialysis, and lots of it, 
is an essential means to clear P, but we 
really mean daily dialysis, which is a 
hard call. So we are left with compounds 
that bind P in the diet. The cornerstone 
of this treatment is calcium-based 
P-binding compounds, namely calcium 
carbonate and calcium acetate. They are 
eﬀective if taken correctly, that is, at the 
time of each meal and in proportion to 
the amount of P in the meal. Of course 
this is rarely explained to the patient, 
because medical staﬀ is hard pressed 
and impatient, and in any event the 
vast majority of patients are not able to 
adhere to such rigorous self-discipline. 
So, the calcium-based P binders are 
taken irregularly—for example, three 
times a day—with little regard for the 
food or the amount of P in each meal. 
In any event, it seemed counterintuitive 
to prescribe calcium salts as a treatment 
when calcium was so obviously visible 
in calciﬁed soft tissues, especially blood 
vessels. So the ﬂag was raised in the race 
to ﬁnd alternative P binders.
Sevelamer hydrochloride was first 
past the ﬁnishing line: a non-calcium-
containing P binder that, to boot, also 
binds low-density lipoprotein choles-
terol. What more can you ask for? Well, 
we would like some hard data in addi-
tion to some well-aimed marketing. Of 
course, the obvious data in experimen-
tal models were soon available, showing 
that it binds P and prevents a whole host 
of complications in uremic rats.3 The 
data in patients on dialysis were more 
diﬃcult to acquire by the very nature of 
the patient population. However, valiant 
attempts were made; but caveats always 
remained for the discerning physician. 
For instance, in an initial study it was 
claimed that the progression of coro-
nary vascular calciﬁcation was slower 
in dialysis patients on sevelamer than 
in those on calcium-based P binders.4 
However, there were large diﬀerences 
between the basal calciﬁcation scores of 
the two groups, making interpretation 
diﬃcult. This was taken into considera-
tion by sophisticated statistical analyses, 
but many were cautious and waited for 
more convincing data. In the meantime 
there were further studies showing its 
eﬀectiveness,5 although another short 
term study showed that calcium acetate 
was more eﬀective at controlling serum 
P and calcium-P product than sevela-
mer.6 Furthermore, although there was 
doubt as to sevelamer’s ability to bind P 
and prevent vascular calciﬁcation, there 
was no doubt that it was a highly eﬀec-
tive cholesterol binder. So a sine qua 
non of objective clinical studies would 
be to also provide the calcium carbon-
ate-treated patients with a cholesterol-
reducing agent such as a statin if we 
were really interested in showing that 
the non-calcium-containing P binder 
was more effective than the calcium 
salt. This has never been done. So dis-
cerning nephrologists still preached 
caution before changing their prescrip-
tions from calcium salts to sevelamer. 
This is especially true given that seve-
lamer is an extremely expensive tablet. 
Nevertheless, what we all awaited was 
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an outcomes study comparing a calcium 
salt to sevelamer.
Outcomes studies in nephrology are 
few and far between, which testiﬁes to 
the heterogeneity of the population of 
dialysis patients, the demands that dialy-
sis imposes on their time and patience, 
and their high morbidity and mortal-
ity. That said, they are a captive audi-
ence who appear at least three times a 
week in the dialysis centers, and they do 
appreciate the necessity and beneﬁts of 
their conﬁnements. The Dialysis Clini-
cal Outcomes Revisited (DCOR) study7 
(this issue) was an outcomes study 
on the effect of a non-calcium-based 
P binder as compared with either calcium 
acetate or calcium carbonate in dialysis 
patients. This was a noble task and, as 
an initial study, one well performed. 
The study was industry-initiated and 
-sponsored, because only industry has 
the means and facilities to undertake 
such an expensive study, and it was 
chaired by an academic nephrologist. 
So what were the ﬁndings? I am afraid 
there is no pithy conclusion, but there 
is a lot to learn from the study. Can we 
draw eﬀective conclusions and now state 
categorically how we should treat our 
patients and advise health-care authori-
ties how to allocate scarce resources? No: 
as always there must be cautious inter-
pretations and conclusions, not the stuﬀ 
of bold headlines and advertisements. We 
do want accurate presentation of data that 
does not overstate the drug’s beneﬁts. So, 
let us look at some of the details.
Over 1,068 patients were followed 
up for a mean of 20 months, and there 
were 542 deaths, of which 53% were 
due to cardiovascular causes.7 These 
stark statistics underline the urgency 
of the clinical problem. There was no 
diﬀerence in cardiovascular mortality 
between the groups. Older patients 
(>65 years) showed a significantly 
lower mortality in the sevelamer group. 
However, this observation must be 
interpreted with caution. Firstly, the 
increased mortality was not due to car-
diovascular deaths. Furthermore, the 
eﬀect on mortality in the opposite direc-
tion for those younger than 65 was just 
as great but did not achieve signiﬁcance 
because of the lower death rates in the 
younger patients. In addition, the divi-
sion into groups less than and greater 
than 65 was a prespeciﬁed analysis but 
not a primary end point. Patient allo-
cation was not performed according to 
this criterion.
So younger patients (<65 years) 
showed a tendency to beneﬁt from cal-
cium-based P binders as compared with 
sevelamer, and patients older than 65 
years had no diﬀerence in cardiovascu-
lar mortality but may have beneﬁted for 
some other reason. The basic assump-
tion and all previous studies suggested 
that sevelamer provides cardiovascular 
protection to dialysis patients because 
it prevents calciﬁcation. This has been 
widely disseminated and accepted by 
many physicians. Now the first out-
comes study suggests that this is not 
correct. Younger patients may very well 
beneﬁt from calcium-based P binders. 
Older patients may beneﬁt from seve-
lamer but not because of an improve-
ment in cardiovascular mortality. This 
age analysis should be interpreted as a 
post hoc analysis and provide the basis 
for a future study on the beneﬁt of any 
P binder over the standard cheap 
calcium carbonate. DCOR was a com-
mendable and ambitious study, and its 
investigators have laid the rules by which 
all non-calcium-based P binders will be 
studied. Our patients deserve outcomes 
study to decide what they should be pre-
scribed, particularly as the newer drugs 
such as lanthanum carbonate and others 
on the horizon are much more expen-
sive and a burden on strained health 
budgets. DCOR has raised the banner 
(Figure 1). It should be pointed out 
that the study has performed a valu-
able service by providing data that will 
serve as a benchmark against which 
other researchers on other studies can 
compare their data. However, it is best 
Figure 1 | DCOR or decoy? Dialysis Clinical Outcomes Revisited (DCOR) was not on target in 
that the primary aim of a reduction in all-cause mortality by sevelamer compared with calcium 
salts was not achieved. A formal post hoc analysis of benefit to older patients should now be 
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interpreted as an expensive learning 
experience, and future trials should be 
aimed at speciﬁc age ranges. The gaunt-
let has now been thrown down for other 
outcomes studies in nephrology, and 
in particular those relevant to mineral 
and bone disorders in patients with 
chronic kidney disease. This includes 
studies on vitamin D metabolites. For 
example, is there any real benefit to 
analogs of 1α,25-dihydroxyvitamin D 
over 1α,25(OH)-vitamin D itself or 
the prodrug 1α(OH)-vitamin D? This 
has never been studied and is an open 
question, and we can only hope that the 
challenges are taken up.
In summary, DCOR was an ambitious 
and well performed study. It really was 
essentially a negative study, as younger 
patients showed a tendency to beneﬁt 
from calcium-based P binders and, in 
older patients, if there was really a beneﬁt 
to sevelamer, it was not shown to be due 
to any change in cardiovascular mortal-
ity. So intuitively it may sound correct to 
give a non-calcium-based P binder, but 
we await DCOR II for a more deﬁnitive 
study to know whether our intuition is 
based on science or skilled marketing.
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Exosomes in urine: Who would have 
thought…?
MA Knepper1 and T Pisitkun1
Normal urine contains thousands of proteins, largely due to the presence 
of  ‘exosomes,’ tiny vesicles secreted into the urine by renal epithelial 
cells. These exosomes, demonstrated by Keller and colleagues to be also 
retrievable from amniotic fluid, offer great promise for future disease 
biomarker discovery studies.
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Who would have thought…? Who would 
have thought that urine could be so complex? 
For hundreds of years, physicians have ana-
lyzed urine in a variety of ways to discover 
what is wrong with their patients.1 Most 
frequently, we divide samples into two 
components (sediments and supernatant) 
and look with interest at the sediments for 
the telltale crystal, cast, or cell that will give 
us a clue to what is happening upstream in 
the kidney. The supernatant, or a sample 
of whole urine, meanwhile is examined 
chemically for a few properties that can 
provide added clues — albumin? glucose? 
hemoglobin? — and skilled physicians 
succeed with these simple measures, even 
today, for the beneﬁt of their patients. We 
have grown comfortable with the idea that 
urine is a very simple ﬂuid.
But new developments have painted a 
diﬀerent picture of normal urine, a picture 
of complexity, and the ﬁndings presented 
by Keller and colleagues2 (this issue) have 
added additional important details.2 The 
ﬁrst signs of complexity were early reports 
from proteomics studies using sensitive 
mass spectrometers that normal urine 
contains hundreds of proteins (albeit at low 
concentrations), including integral mem-
brane proteins.3,4 Another sign was the 
discovery that urine contains solid-phase 
elements that remain in the supernatant at 
standard centrifugation speeds for most 
laboratory centrifuges, but which can be 
pelleted at much higher centrifugation 
speeds, that is, via ultracentrifugation. 
A major component of these high-speed 
sediments turned out to be ‘exosomes,’ 
tiny (40–80 nm) membranous structures 
secreted by epithelial cells5 (Figure 1a). 
These urinary exosomes were demon-
strated to contain abundant aquaporin-2, 
providing an explanation for the earlier 
unexplained ﬁnding that the water chan-
nel aquaporin-2, an integral membrane 
protein, was plentiful in urine.6 It turns 
out that many of the myriad of proteins 
detected in urine by mass spectrometry 
in those early proteomics studies are there 
because of the presence of exosomes in 
normal urine.
Exosomes are membrane-bound vesi-
cles that originate as the internal vesicles 
of multivesicular bodies (MVBs; Figure 
1b) in various cell types and are released to 
the extracellular environment by fusion of 
the outer membrane of the MVBs with the 
plasma membrane. Exosomes were previ-
ously known to be produced by many cell 
types, including B lymphocytes and eryth-
rocytes, from which they are delivered 
into the blood. The ﬁnding of exosomes in 
the urine (Figure 1a) opened up new pos-
sibilities for the diagnosis of kidney dis-
eases. Pisitkun et al.5 carried out tandem 
mass spectrometric proﬁling of proteins 
present in urinary exosomes from normal 
human subjects and found 295 distinct 
proteins, at least 22 of which had already 
been implicated in various kidney and sys-
temic abnormalities. Subsequent studies 
using more sensitive mass spectrometric 
